- Home
- DIAX vs LAB Comparison
DIAX vs LAB Comparison
Compare DIAX & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- LAB
- Stock Information
- Founded
- DIAX 2005
- LAB 1999
- Country
- DIAX United States
- LAB United States
- Employees
- DIAX N/A
- LAB N/A
- Industry
- DIAX Finance Companies
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- DIAX Finance
- LAB Industrials
- Exchange
- DIAX Nasdaq
- LAB Nasdaq
- Market Cap
- DIAX 537.5M
- LAB 473.2M
- IPO Year
- DIAX N/A
- LAB 2011
- Fundamental
- Price
- DIAX $14.47
- LAB $1.37
- Analyst Decision
- DIAX
- LAB Buy
- Analyst Count
- DIAX 0
- LAB 2
- Target Price
- DIAX N/A
- LAB $2.50
- AVG Volume (30 Days)
- DIAX 96.6K
- LAB 1.2M
- Earning Date
- DIAX 01-01-0001
- LAB 10-29-2025
- Dividend Yield
- DIAX 7.93%
- LAB N/A
- EPS Growth
- DIAX N/A
- LAB N/A
- EPS
- DIAX N/A
- LAB N/A
- Revenue
- DIAX N/A
- LAB $172,271,000.00
- Revenue This Year
- DIAX N/A
- LAB N/A
- Revenue Next Year
- DIAX N/A
- LAB N/A
- P/E Ratio
- DIAX N/A
- LAB N/A
- Revenue Growth
- DIAX N/A
- LAB 76.33
- 52 Week Low
- DIAX $12.80
- LAB $0.92
- 52 Week High
- DIAX $15.12
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- DIAX 42.24
- LAB 58.09
- Support Level
- DIAX $14.64
- LAB $1.27
- Resistance Level
- DIAX $14.82
- LAB $1.41
- Average True Range (ATR)
- DIAX 0.10
- LAB 0.08
- MACD
- DIAX -0.02
- LAB 0.01
- Stochastic Oscillator
- DIAX 20.45
- LAB 80.95
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.